Clinical characteristics and patient outcomes of molecular subtypes of small cell lung cancer (SCLC)

World Journal of Surgical Oncology

Xia Yang¹  Xiao-Zhen Chen²  Ren Zhao³  Yan-Yang Wang³  Zhou-Lan Bai³  Xue-Hong Bai³  Xiao-Long Ding⁴  Liang Yu⁵  Jin-Xi He⁵  Yi-Ge Su⁶ 

[1] Department of Medical Record, General Hospital of Ningxia Medical University, 750004, Yinchuan, Ningxia, China;Department of Pathology, General Hospital of Ningxia Medical University, 750004, Yinchuan, Ningxia, China;Department of Radiation Oncology, General Hospital of Ningxia Medical University, 750004, Yinchuan, Ningxia, China;Cancer Institute, Ningxia Medical University, 750004, Yinchuan, Ningxia, China;Department of Radiation Oncology, General Hospital of Ningxia Medical University, 750004, Yinchuan, Ningxia, China;Graduate School, Ningxia Medical University, 750004, Yinchuan, Ningxia, China;Cancer Institute, Ningxia Medical University, 750004, Yinchuan, Ningxia, China;Department of Thoracic Surgery, General Hospital of Ningxia Medical University, 750004, Yinchuan, Ningxia, China;Graduate School, Ningxia Medical University, 750004, Yinchuan, Ningxia, China;

关键词: Small cell lung cancer;    Molecular subtype;    ASCL1;    NEUROD1;    POU2F3;    Prognosis;   

DOI  :  10.1186/s12957-022-02528-y

来源: Springer

【 摘 要 】

BackgroundRecent studies have shown that according to the expression levels of achaete-scute homolog 1 (ASCL1), neurogenic differentiation factor 1 (NEUROD1), and POU class 2 homeobox 3 (POU2F3), small cell lung cancer (SCLC) can be divided into four subtypes: SCLC-A (ASCL1-dominant), SCLC-N (NEUROD1-dominant), SCLC-P (POU2F3-dominant), and SCLC-I (triple negative or SCLC-inflamed). However, there are limited data on the clinical characteristics and prognosis of molecular subtypes of SCLC.MethodsImmunohistochemistry (IHC) was used to detect the expression levels of ASCL1, NEUROD1, and POU2F3 in 53 patient samples of resectable SCLC. The subtype was defined by the differential expression of the transcription factors for ASCL1, NEUROD1, and POU2F3 or the low expression of all three factors with an inflamed gene signature (SCLC-A, SCLC-N, SCLC-P, and SCLC-I, respectively). The clinicopathological characteristics, immunological features (programmed death ligand 1 [PD-L1] expression and CD8+ tumor infiltrating lymphocyte [TIL] density), and patient outcomes of the four subtypes of SCLC were analyzed.ResultsPositive ASCL1, NEUROD1, and POU2F3 staining was detected in 43 (79.2%), 27 (51.0%), and 17 (32.1%) SCLC specimens by IHC. According to the results of IHC analysis, SCLC was divided into four subtypes: SCLC-A (39.6%), SCLC-N (28.3%), SCLC-P (17.0%), and SCLC-I (15.1%). The 5-year overall survival (OS) rates of these four subtypes were 61.9%, 69.3%, 41.7%, and 85.7%, respectively (P=0.251). There were significant differences in smoking status among different subtypes of SCLC (P= 0.031). However, we did not confirm the correlation between subtypes of SCLC and other clinicopathological factors or immune profiles. Cox multivariate analysis showed that N stage (P=0.025), CD8+ TILs (P=0.024), Ki-67 level (P=0.040), and SCLC-P (P=0.023) were independent prognostic factors for resectable SCLC.ConclusionsOur IHC-based study validated the proposed classification of SCLC using the expression patterns of key transcriptional regulatory factors. We found that SCLC-P was associated with smokers and was one of the poor prognostic factors of limited-stage SCLC. In addition, no correlation was found between PD-L1 expression or CD8+ TIL density and SCLC subtypes.

【 授权许可】

CC BY